How to Support Rare Disease Patients During COVID-19

Posted by Michael Thomas on Thu, Mar 26, 2020

Greg Fry co-wrote this blog post with Michael Thomas.

Members of the rare disease community—patients, families and caregivers—are accustomed to managing life in crisis mode, cancelling plans at the first sign of illness and feeling isolated, but the pandemic has introduced a new level of concern. With so much focus on COVID-19, rare disease patients are left with fear and uncertainty over healthcare systems’ bandwidth to accommodate their needs. It’s possible that they could experience critical gaps in care like product shortages, fewer healthcare workers available to administer drugs and difficulty getting to infusion appointments. Unfortunately, the response to many of today’s questions about what the novel coronavirus means for rare disease patients is, “We don’t know, exactly.” But we need to ensure that we’re exploring new alternatives and thinking creatively to develop solutions that either ease these tensions for patients or create bridges that are meaningful, empathetic, supportive and, of course, compliant.


>
Read More

Designing Effective Incentive Plans for Rare Disease Teams

Posted by Michael Thomas on Mon, Feb 13, 2017

While the pharmaceutical industry is still just skimming the surface when it comes to developing therapies to address the 7,000-plus known rare diseases, drug development is only half of the battle. Organizations that have successfully gained approval for their therapies in the U.S. and abroad face significant challenges when planning their commercial efforts and developing incentive strategies for the field force. To succeed, they often have to get creative.


>
Read More

Changing the Mindset: Success in Commercializing Rare Disease Drugs

Posted by Michael Thomas on Tue, Apr 26, 2016

There are currently only 314 FDA-approved therapies available among the roughly 7,000 rare diseases that have been identified, according to the Genetic and Rare Diseases Information Center. The global pharmaceutical industry recognizes the unmet need and the opportunity to solve the challenges associated with patients with rare diseases. Current and future pipeline assets offer the pharmaceutical industry an opportunity to bring to market the type of life-changing therapies for patients that add true value where hope is limited.


>
Read More